• Platform
  • Pipeline
  • Team
Biomia
  • Resources
  • Contact

Nature’s pharmacy, re-engineered

Biomia rationally engineers nature-inspired novel small molecule therapeutics to treat CNS disorders.

Problem

There is an undeniable global crisis with CNS disorders

760M

People worldwide suffering from mental health disorders

1.5B

People worldwide who endure consistent pain

Potential

Nature-derived therapeutics are one of our best tools for treating CNS disorders—but they’re still not good enough

Pain

Commonly used compound

Morphine

The chemical structure for Morphine.

Treats

Acute Pain

Doesn’t Treat

Neuropathic pain, chronic pain

Side effect

Tolerance, respiratory depression, addiction

40% of approved CNS therapeutics are derived from nature, however, current therapeutics with similar MOAs are inadequate and leave symptoms untreated with devastating side effects ranging from seizures to addiction.

Mental health disorders

Commonly used compound

Quetiapine

The chemical structure for Quetiapine

Treats

Hallucinations & delusions

Doesn’t Treat

Cognitive deficits, negative symptoms

Side effect

Sedation, weight gain, cardiac arrest

Platform

Biomia is optimizing and scaling nature-inspired molecules for therapeutic use

Optimization

Lead optimization from nature-inspired compound libraries

Biomia engineers novel CNS therapeutics using a proprietary platform that combines AI-driven discovery with yeast-based biomanufacturing to produce enantiopure, bioactive molecules with superior therapeutic potential.

Engineering

Genetically engineered yeast synthesizes patentable enantiopure drug candidates

Manufacturing

Scalable manufacturing of novel nature-inspired therapies

Pipeline

10 years ahead in discovering drug candidates through links between bioactivity and the CNS

A table showing drug development progress for three compounds. The table has columns for Compound, Indication, Hit ID, Lead, Lead discovery, Optimization, IND, and Clinical. The compounds are:

Stemmadenine analogue for Chronic/Neuropathic pain, with progress bars in Hit ID, Lead, and Lead discovery stages.
Yohimbane analogue for Schizophrenia/Bipolar disorder, with progress bars in Hit ID and Lead stages.
Iboga analogue for Opioid Use Disorder, with progress bars in Hit ID and Lead stages.

The progress bars use shades of blue to indicate advancement in each stage.

Team

A proven team of synthetic biology leaders & industry professionals to unleash nature’s bioactive potential.

Michael K. Jensen

Michael K. Jensen

CEO

15+ years in biotechnology, public:private R&D partnerships, 70+ publications, 4 patents.

Jie Zhang

Jie Zhang

CSO

15+ years in metabolic engineering and synthetic biology, 20+ publications, 3 patents.

Jay D. Keasling

Jay D. Keasling

Board Member

UC Berkeley Professor, 500+ publications, 65+ patents, founder of 10 synbio companies..

Henrik Stage

Henrik Stage

Board Chairman

Serial entrepreneur, raised $250M+, expert in pharma deals, IPOs, and M&As.

Juliet Kinuya

Juliet Kinuya

Sr. Analytical Chemist

Expert in analytical chemistry and forensic toxicology, former scientist at Biosyntia.

Lea G. Hansen

Lea G. Hansen

R&D Lead

Biochemist, yeast cell factory specialist, 10+ publications, 3 patents.

Olga Gudich

Olga Gudich

Scientist

Chemist with research experience at Lomonosov MSU, BII, and SRC Bioclinicum.

Russell Thomas

Russell Thomas

Advisor

Medicinal chemist, CNS, Strategic alliance networking on medicinal chemistry. Head of Business Development at Symere.

Sebastian Søderberg

Sebastian Søderberg

Advisor

20+ years in business incubation, M&A, CEO of Bactolife, advisor to BII.

News & Resources

News

March 8, 2024

teemi: An open-source literate programming approach for iterative design-build-test-learn cycles in bioengineering

Journal: PLOS Computational Biology
News

March 8, 2024

teemi: An open-source literate programming approach for iterative design-build-test-learn cycles in bioengineering

Journal: PLOS Computational Biology
News

November 6, 2023

Biosynthesis of natural and halogenated plant monoterpene indole alkaloids in yeast

Journal: Nature Chemical Biology
News

November 6, 2023

Biosynthesis of natural and halogenated plant monoterpene indole alkaloids in yeast

Journal: Nature Chemical Biology
News

September 26, 2023

Biomia Secures $3.0 Million in Pre-seed Financing

Announcement
News

September 26, 2023

Biomia Secures $3.0 Million in Pre-seed Financing

Announcement
News

August 31, 2022

A microbial supply chain for production of the anti-cancer drug vinblastine

Journal: Nature
News

August 31, 2022

A microbial supply chain for production of the anti-cancer drug vinblastine

Journal: Nature
News

September 25, 2020

Combining mechanistic and machine learning models for predictive engineering and optimization of tryptophan metabolism

Journal: Nature Communications
News

September 25, 2020

Combining mechanistic and machine learning models for predictive engineering and optimization of tryptophan metabolism

Journal: Nature Communications

Work with us to explore the new frontiers of nature-inspired drug design

Biomia innovates from biology, chemistry and pharmacoengineering to address unmet patient needs. With determination, collaboration, and excellence in biotechnology and drug discovery, we are committed to develop a new generation of safe and efficient CNS therapeutics.

If you want to learn more about the work at Biomia, or share our goal of creating better solutions for patients, contact us.

gen o wayHelsinki UniversityUKM
gen o wayHelsinki UniversityUKM
gen o wayHelsinki UniversityUKM

Contact us

Success
A member of our team will be in touch with you shortly.
Oops! Something went wrong while submitting the form.

© 2024 Biomia. All rights reserved.

PrivacyLinkedInSite by Bunsen